BACKGROUND: The prognosis for children with M1 medulloblastoma (positive CSF cytology) has not been well-defined. METHODS: We retrospectively reviewed the records of 285 newly diagnosed medulloblastoma patients treated between 1984 and 2006. Older children received post-operative craniospinal and tumor bed irradiation; radiotherapy for younger children depended on treatment era and physician/family preference. RESULTS: 55 patients were <3 years old and 230 patients were >or= 3 years old at diagnosis. We detected significant (P < 0.0001) associations between M1 disease and EFS for the entire cohort and for both younger and older patients. Among younger children, M1 patients had lower EFS than M0 (P = 0.0044). CONCLUSIONS: Children <3 years old with M1 medulloblastoma fared poorly in our small series. Survival for older children with M1 disease treated with higher-dose CSI was better than that of M2/M3 patients, but still less than optimal; our findings do not support reduction in therapy for either cohort.
BACKGROUND: The prognosis for children with M1 medulloblastoma (positive CSF cytology) has not been well-defined. METHODS: We retrospectively reviewed the records of 285 newly diagnosed medulloblastomapatients treated between 1984 and 2006. Older children received post-operative craniospinal and tumor bed irradiation; radiotherapy for younger children depended on treatment era and physician/family preference. RESULTS: 55 patients were <3 years old and 230 patients were >or= 3 years old at diagnosis. We detected significant (P < 0.0001) associations between M1 disease and EFS for the entire cohort and for both younger and older patients. Among younger children, M1 patients had lower EFS than M0 (P = 0.0044). CONCLUSIONS:Children <3 years old with M1 medulloblastoma fared poorly in our small series. Survival for older children with M1 disease treated with higher-dose CSI was better than that of M2/M3 patients, but still less than optimal; our findings do not support reduction in therapy for either cohort.
Authors: Susan N Chi; Sharon L Gardner; Adam S Levy; Edmond A Knopp; Douglas C Miller; Jeffrey H Wisoff; Howard L Weiner; Jonathan L Finlay Journal: J Clin Oncol Date: 2004-12-15 Impact factor: 44.544
Authors: Amar Gajjar; Murali Chintagumpala; David Ashley; Stewart Kellie; Larry E Kun; Thomas E Merchant; Shaio Woo; Greg Wheeler; Valerie Ahern; Matthew J Krasin; Maryam Fouladi; Alberto Broniscer; Robert Krance; Gregory A Hale; Clinton F Stewart; Robert Dauser; Robert A Sanford; Christine Fuller; Ching Lau; James M Boyett; Dana Wallace; Richard J Gilbertson Journal: Lancet Oncol Date: 2006-10 Impact factor: 41.316
Authors: Susan M Blaney; James Boyett; Henry Friedman; Amar Gajjar; Russ Geyer; Marc Horowtiz; Daniel Hunt; Mark Kieran; Larry Kun; Roger Packer; Peter Phillips; Ian F Pollack; Michael Prados; Richard Heideman Journal: J Clin Oncol Date: 2005-01-20 Impact factor: 44.544
Authors: P K Duffner; M E Horowitz; J P Krischer; P C Burger; M E Cohen; R A Sanford; H S Friedman; L E Kun Journal: Neuro Oncol Date: 1999-04 Impact factor: 12.300
Authors: R D Kortmann; J Kühl; B Timmermann; U Mittler; C Urban; V Budach; E Richter; N Willich; M Flentje; F Berthold; I Slavc; J Wolff; C Meisner; O Wiestler; N Sörensen; M Warmuth-Metz; M Bamberg Journal: Int J Radiat Oncol Biol Phys Date: 2000-01-15 Impact factor: 7.038
Authors: Stefan Rutkowski; Udo Bode; Frank Deinlein; Holger Ottensmeier; Monika Warmuth-Metz; Niels Soerensen; Norbert Graf; Angela Emser; Torsten Pietsch; Johannes E A Wolff; Rolf D Kortmann; Joachim Kuehl Journal: N Engl J Med Date: 2005-03-10 Impact factor: 91.245
Authors: J R Geyer; P M Zeltzer; J M Boyett; L B Rorke; P Stanley; A L Albright; J H Wisoff; J M Milstein; J C Allen; J L Finlay Journal: J Clin Oncol Date: 1994-08 Impact factor: 44.544
Authors: P K Duffner; M E Horowitz; J P Krischer; H S Friedman; P C Burger; M E Cohen; R A Sanford; R K Mulhern; H E James; C R Freeman Journal: N Engl J Med Date: 1993-06-17 Impact factor: 91.245
Authors: B I Razzouk; R L Heideman; H S Friedman; J J Jenkins; L E Kun; D L Fairclough; M E Horowitz Journal: Cancer Date: 1995-06-01 Impact factor: 6.860
Authors: Lucie Lafay-Cousin; Amy Smith; Susan N Chi; Elizabeth Wells; Jennifer Madden; Ashley Margol; Vijay Ramaswamy; Jonathan Finlay; Michael D Taylor; Girish Dhall; Douglas Strother; Mark W Kieran; Nicholas K Foreman; Roger J Packer; Eric Bouffet Journal: Pediatr Blood Cancer Date: 2016-05-04 Impact factor: 3.167
Authors: Danning Huang; Jingbo Liu; Ronald C Eldridge; David A Gaul; Martin R L Paine; Karan Uppal; Tobey J MacDonald; Facundo M Fernández Journal: Anal Bioanal Chem Date: 2020-08-14 Impact factor: 4.142
Authors: Dimitra Tripolitsioti; Karthiga Santhana Kumar; Anuja Neve; Jessica Migliavacca; Charles Capdeville; Elisabeth J Rushing; Min Ma; Noriyuki Kijima; Ashish Sharma; Martin Pruschy; Scott McComb; Michael D Taylor; Michael A Grotzer; Martin Baumgartner Journal: Oncotarget Date: 2018-05-01
Authors: Rebecca M Hill; Sabine L A Plasschaert; Beate Timmermann; Christelle Dufour; Kristian Aquilina; Shivaram Avula; Laura Donovan; Maarten Lequin; Torsten Pietsch; Ulrich Thomale; Stephan Tippelt; Pieter Wesseling; Stefan Rutkowski; Steven C Clifford; Stefan M Pfister; Simon Bailey; Gudrun Fleischhack Journal: Cancers (Basel) Date: 2021-12-28 Impact factor: 6.575
Authors: Denise Obrecht; Martin Mynarek; Christian Hagel; Robert Kwiecien; Michael Spohn; Michael Bockmayr; Brigitte Bison; Stefan M Pfister; David T W Jones; Dominik Sturm; Andreas von Deimling; Felix Sahm; Katja von Hoff; B-Ole Juhnke; Martin Benesch; Nicolas U Gerber; Carsten Friedrich; André O von Bueren; Rolf-Dieter Kortmann; Rudolf Schwarz; Torsten Pietsch; Gudrun Fleischhack; Ulrich Schüller; Stefan Rutkowski Journal: J Neurooncol Date: 2022-02-21 Impact factor: 4.130